Sees FY25 adjusted EBITDA of $295 million to $335 million, reflecting an Adjusted EBITDA margin of 13% to 14%.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Hims and Hers Health options imply 14.9% move in share price post-earnings
- Hims & Hers Health (HIMS) Is About to Report Q2 Earnings. Here’s What to Expect
- Options Volatility and Implied Earnings Moves Today, August 04, 2025
- Is HIMS a Buy, Before Earnings?
- Option traders moderately bearish in Hims and Hers Health with shares down 5.67%